KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $702.0 million.

  • Halozyme Therapeutics' Cash & Current Investments rose 5.35% to $702.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 30.05%. This contributed to the annual value of $596.1 million for FY2024, which is 77.40% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Cash & Current Investments stood at $702.0 million, which was up 28.05% from $548.2 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Cash & Current Investments peaked at $815.9 million during Q3 2021, and registered a low of $209.4 million during Q2 2022.
  • Over the past 3 years, Halozyme Therapeutics' median Cash & Current Investments value was $529.0 million (recorded in 2024), while the average stood at $517.8 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Cash & Current Investments skyrocketed by 135.33% in 2021 and then tumbled by 72.28% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Cash & Current Investments (Quarterly) stood at $740.9 million in 2021, then crashed by 51.03% to $362.8 million in 2022, then dropped by 7.39% to $336.0 million in 2023, then surged by 77.40% to $596.1 million in 2024, then climbed by 5.35% to $702.0 million in 2025.
  • Its Cash & Current Investments stands at $702.0 million for Q3 2025, versus $548.2 million for Q2 2025 and $747.9 million for Q1 2025.